Clinical trials: Metastatic
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase II trial studies the side effects and best dose of iodine I 131 monoclonal antibody BC8 when given together with fludarabine phosphate, total-body irradiation, and donor stem cell transplant followed by cyclosporine…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00119366
- Testing
- iodine I 131 monoclonal antibody BC8, fludarabine phosphate, total-body irradiation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Kidney Disease, Secondary Hyperparathyroidism
Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)
The aims of this post-marketing observational study (PMOS) are to evaluate the time period needed to achieve > 30% decrease of intact parathyroid hormone (iPTH) compared to the initial values and to provide data on the…
- Trial name
- NCT01224782
- Where
- 69 sites in Bulgaria, Czechia and 1 more
- Volunteers
- 994 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Decitabine may help myelodysplastic cells become more like normal stem cells. PURPOSE: This clinical trial studies differentiation therapy with decitabine in treating patients with myelodysplastic syndrome.
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Refractory Anemia
- Trial name
- NCT01165996
- Testing
- flow cytometry, DNA methylation analysis, cytogenetic analysis
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
This study aimed to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or…
- Conditions
- Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin, Well-differentiated Non-functional NET of Pancreatic Origin, Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02955069
- Testing
- PDR001
- Where
- 35 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
This phase II trial studies how well letrozole, anastrozole, or fulvestrant work when given together with ribociclib, palbociclib, and/or abemaciclib in treating patients with hormone receptor (HR) positive breast cancer that has…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT04256941
- Testing
- Abemaciclib, Anastrozole, Fulvestrant
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
The purpose of this study is to see if a combination of drugs can help to treat this type of cancer. One drug is a chemotherapy agent called paclitaxel (Taxol®). Paclitaxel will be given every week through the vein.
- Trial name
- NCT01276041
- Testing
- pertuzumab in combination with trastuzumab and paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 70 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer Metastatic
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human…
- Trial name
- NCT04215146
- Testing
- Paclitaxel, Pelareorep, Avelumab
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- Oncolytics Biotech
Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
This phase II trial studies how well giving phenelzine sulfate together with docetaxel works in treating patients with prostate cancer that is growing, spreading, or getting worse after first-line therapy with docetaxel.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT01253642
- Testing
- Biopsy of Prostate, Docetaxel, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Colorectal Cancer
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic…
- Trial name
- NCT02788279
- Testing
- Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
- Where
- 73 sites in United States, Australia and 9 more
- Volunteers
- 363 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Lung Cancer Metastatic
Safety of PDT-Photofrin® Prior to Lung Surgery
This research study is being conducted to assess the safety of PDT in subjects with peripherally located malignant tumors in lung parenchyma prior to surgical resection. It will involve up to 10 sites in USA.
- Trial name
- NCT03344861
- Testing
- Porfimer Sodium, Fiber optic
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Concordia Laboratories Inc.
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability
- Trial name
- ATLANTIC (NCT02087423)
- Testing
- MEDI4736
- Where
- 139 sites in United States, Austria and 16 more
- Volunteers
- 446 people
- Sponsor
- AstraZeneca
Metastatic Solid Tumor
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.
- Trial name
- TROPiCS-03 (NCT03964727)
- Testing
- Sacituzumab Govitecan-hziy
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 227 people
- Sponsor
- Gilead Sciences
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreas Metastases
- Trial name
- NABPLAGEMD (NCT03415854)
- Testing
- Paricalcitol (Zemplar)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- HonorHealth Research Institute
Unresectable or Metastatic Melanoma
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.
- Trial name
- NCT01844505
- Testing
- Nivolumab, Ipilimumab
- Where
- 150 sites in United States, Australia and 20 more
- Volunteers
- 945 people
- Sponsor
- Bristol-Myers Squibb
Hematologic Diseases, Secondary Immune Deficiency
Comparison of Multigam IV (5% vs. 10%) in Patients With an Immunodeficiency Secondary to a Hematological Disorder
The purpose of this observational study is to compare the administration of standard of care Multigam IV 5% and standard of care Multigam IV 10% in order to observe changes in infusion time and infusion related reactions.
- Trial name
- MULTISIM (NCT03250845)
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
This randomized, 3-arm, multicenter, phase III study will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) with pertuzumab or trastuzumab emtansine (T-DM1) with pertuzumab-placebo (blinded for pertuzumab), versus…
- Trial name
- NCT01120184
- Testing
- docetaxel, paclitaxel, pertuzumab
- Where
- 257 sites in United States, Argentina and 36 more
- Volunteers
- 1,095 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic…
- Trial name
- NCT04656652
- Testing
- DS-1062a, Docetaxel
- Where
- 209 sites in United States, Argentina and 24 more
- Volunteers
- 605 people
- Sponsor
- Daiichi Sankyo
Metastatic Cancer
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type.
- Trial name
- MODULATE (NCT03009058)
- Testing
- IMM-101, Gemcitabine, Nab-paclitaxel
- Where
- 4 sites in France, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Immodulon Therapeutics Ltd
Meningococcal Infection
Immunogenicity of the Booster Dose of Two MenC Vaccines
The purpose of the study is to evaluate the immune response of toddlers, to a booster dose in the second year of life of two meningococcal C conjugated polysaccharide vaccine, and to assess the interchangeability of the two…
- Trial name
- CSISP-MENC1 (NCT00392808)
- Testing
- conjugated polysaccharide menC vaccine
- Where
- 2 sites in Spain
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Centro Superior de Investigación en Salud Publica
Advanced/Metastatic Breast Cancer
Study Of Sunitinib With Capecitabine In Breast Cancer
To evaluate efficacy, safety and pharmacokinetics of sunitinib plus Capecitabine in Japanese patients with advanced/metastatic breast cancer.
- Trial name
- NCT00662025
- Testing
- Capecitabine, Sunitinib
- Where
- 17 sites in Japan
- Volunteers
- 63 people
- Sponsor
- Pfizer
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.